Epigenetics: How does obesity lead to insulin resistance?
Experiments on mice show that an enzyme called DNA methyltransferase 3a is involved in insulin resistance via an epigenetic mechanism.
- The Rockefeller University, United States
Insulin is a hormone produced by the pancreas that regulates the concentration of glucose in the blood (Saltiel and Kahn, 2001; Taniguchi et al., 2006). Following a meal, insulin secretion increases glucose uptake in muscle and fat, and reduces the production of glucose by the liver, enabling blood glucose levels to be maintained within a precise range. However, in cases of chronic overnutrition, the body can become less responsive to insulin, leading to a state known as insulin resistance. Initially, the pancreas responds by secreting more insulin, but when this can no longer compensate for the impaired insulin response of the liver and other organs, type 2 diabetes develops (Prentki and Nolan, 2006).
Insulin resistance serves as a key link between obesity and type 2 diabetes (Kahn and Flier, 2000), and understanding how obesity causes insulin resistance will improve our knowledge of type 2 diabetes and our ability to treat obesity-related complications. It is likely that the development of obesity-induced insulin resistance involves a complex interplay of genetic and environmental factors (Samuel and Shulman, 2012).
One mechanism by which cells can integrate signals from the environment is through epigenetic changes: these are changes that modify DNA or the proteins that organize the DNA within cells without changing the underlying DNA sequence (Jaenisch and Bird, 2003). DNA methylation, for example, is an epigenetic change that involves adding a methyl group to a cytosine base that is upstream of guanosine. Islands of these CpG sequences are often found in the gene promoters near the start of genes, and the methylation of these bases usually reduces gene expression. Now, in eLife, Sona Kang, Evan Rosen and colleagues in the USA, Denmark and Sweden – including Dongjoo You of the University of California Berkeley as first author – report how a key epigenetic regulator called Dnmt3a contributes to obesity-related insulin resistance (You et al., 2017).
The DNA methyltransferase (Dnmt) family of enzymes catalyze the methylation of DNA (Denis et al., 2011). You et al. noticed that fat cells taken from obese mice contained high levels of two DNA methyltransferases, and experiments on fat cells grown in the laboratory suggested that one of these enzymes – Dnmt3a – had a role in the development of insulin resistance. When the researchers knocked down or inhibited Dnmt3a, the fat cells were able to take up more glucose in response to insulin, even when they had been treated with substances that induce insulin resistance. Similar results were observed in genetically engineered mice that lacked Dnmt3a in their fat cells. When placed on a high fat diet, the knockout mice gained the same amount of weight as wild-type mice, but they demonstrated improved glucose and insulin tolerance, and their fat cells responded more strongly to insulin.
You et al. then performed a screen to check if blocking or overexpressing Dnmt3a changed the level of transcription of various genes. They found that a gene called Fgf21, which encodes a secreted protein that helps fat cells to absorb glucose (Kharitonenkov et al., 2005), was transcribed less when Dnmt3a was overexpressed. Fgf21 is predominantly secreted by the liver, but fat cells are also known to express Fgf21. Based on their findings, You et al. suggest that Dnmt3a can induce insulin resistance in fat cells by methylating the CpG islands in the Fgf21 promoter region. This reduces the expression of Fgf21 genes, which in turn makes fat cells more resistant to insulin. Similar mechanisms might also be at play in human fat cells: people with diabetes had higher methylation levels near the FGF21 gene compared to people without diabetes, and the degree of methylation was also inversely correlated with the levels of FGF21 mRNA.
While insulin resistance may play a fundamental role in the development of type 2 diabetes in obese individuals, currently available anti-diabetic agents that target insulin resistance are limited to a single class of drugs called thiazolidinediones, which are no longer widely used due to potential side effects (Yki-Järvinen, 2004). DNA methylation has been an attractive therapeutic target in other clinical contexts, such as cancer. Therefore, targeting Dnmt3a or Fgf21 could provide new treatment opportunities for obesity-related complications such as insulin resistance.
You et al.’s study raises several key questions that could be addressed in future studies. First, the mechanism underlying the upregulation of Dnmt3a in obesity is not clear. Second, the repression of Fgf21 appears to explain only some of the downstream actions of Dnmt3a. Further research may be able to identify additional genes and pathways that are regulated by Dnmt3a, which could help with the development of alternative treatments for insulin resistance.
References
-
Obesity and insulin resistanceJournal of Clinical Investigation 106:473–481.https://doi.org/10.1172/JCI10842
-
FGF-21 as a novel metabolic regulatorJournal of Clinical Investigation 115:1627–1635.https://doi.org/10.1172/JCI23606
-
Islet beta cell failure in type 2 diabetesJournal of Clinical Investigation 116:1802–1812.https://doi.org/10.1172/JCI29103
-
Critical nodes in signalling pathways: insights into insulin actionNature Reviews Molecular Cell Biology 7:85–96.https://doi.org/10.1038/nrm1837
-
ThiazolidinedionesNew England Journal of Medicine 351:1106–1118.https://doi.org/10.1056/NEJMra041001
Article and author information
Author details
Publication history
Copyright
© 2017, Choi et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 3,851
- views
-
- 433
- downloads
-
- 18
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Epigenetics: How does obesity lead to insulin resistance?
eLife 6:e33298.
https://doi.org/10.7554/eLife.33298
Further reading
-
- Cell Biology
Epithelial damage leads to early reactive oxygen species (ROS) signaling, which regulates sensory neuron regeneration and tissue repair. How the initial type of tissue injury influences early damage signaling and regenerative growth of sensory axons remains unclear. Previously we reported that thermal injury triggers distinct early tissue responses in larval zebrafish. Here, we found that thermal but not mechanical injury impairs sensory axon regeneration and function. Real-time imaging revealed an immediate tissue response to thermal injury characterized by the rapid Arp2/3-dependent migration of keratinocytes, which was associated with tissue scale ROS production and sustained sensory axon damage. Isotonic treatment was sufficient to limit keratinocyte movement, spatially restrict ROS production, and rescue sensory neuron function. These results suggest that early keratinocyte dynamics regulate the spatial and temporal pattern of long-term signaling in the wound microenvironment during tissue repair.
-
- Cell Biology
Meiotic progression requires coordinated assembly and disassembly of protein complexes involved in chromosome synapsis and meiotic recombination. Mouse TRIP13 and its ortholog Pch2 are instrumental in remodeling HORMA domain proteins. HORMAD proteins are associated with unsynapsed chromosome axes but depleted from the synaptonemal complex (SC) of synapsed homologs. Here we report that TRIP13 localizes to the synapsed SC in early pachytene spermatocytes and to telomeres throughout meiotic prophase I. Loss of TRIP13 leads to meiotic arrest and thus sterility in both sexes. Trip13-null meiocytes exhibit abnormal persistence of HORMAD1 and HOMRAD2 on synapsed SC and chromosome asynapsis that preferentially affects XY and centromeric ends. These major phenotypes are consistent with reported phenotypes of Trip13 hypomorph alleles. Trip13 heterozygous mice exhibit meiotic defects that are less severe than the Trip13-null mice, showing that TRIP13 is a dosage-sensitive regulator of meiosis. Localization of TRIP13 to the synapsed SC is independent of SC axial element proteins such as REC8 and SYCP2/SYCP3. Terminal FLAG-tagged TRIP13 proteins are functional and recapitulate the localization of native TRIP13 to SC and telomeres. Therefore, the evolutionarily conserved localization of TRIP13/Pch2 to the synapsed chromosomes provides an explanation for dissociation of HORMA domain proteins upon synapsis in diverse organisms.
